Unified eClinical solutions provider Axiom Real-Time Metrics has announced its partnership with the University of Oxford for its clinical trial focused on the preventative treatments of Covid-19.
Named COPCOV, the trial is led by the University of Oxford-supported Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is designed to recruit 40,000 frontline healthcare workers and staff in Europe, Africa, Asia, and South America.
The study began in April this year. It will run for one year and is currently the ‘largest interventional trial’ being conducted at a global level.
Axiom’s eClinical suite Fusion will deliver tools required for electronic data collection and electronic patient-reported outcomes.
Axiom founder and CEO Andrew Schachter said: “We are honoured that the University of Oxford and its collaborators have placed their trust in Axiom with respect to the criticality of the of real-time capture of clinical daily patient reported outcomes to this study and the management of its trial data.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Over the past 20 years, Axiom has supported trials of global importance, and this study is no exception. Indeed, it is unprecedented in many aspects. Playing our part to enable this study is a point of pride for the entire Axiom global team.”
Fusion will also deliver randomisation and reporting functions for the study.
Mahidol Oxford Research Unit data management head Naomi Waithira said: “It’s been a pleasure working with the Axiom team as we rapidly configured this study in just a few weeks. I greatly appreciate their contributions to our research.”
In March this year, Researchers at the University of Oxford in the UK commenced enrolment of healthy volunteers for a clinical trial of the Covid-19 vaccine candidate ChAdOx1 nCoV-19.
